Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_276164141bff1b671b52ceb89dd1b779 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-585 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6037 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-804 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-43 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-73 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-085 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-31 |
filingDate |
2018-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d22c2b4c0617af1b14247664a9675885 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b274e419f707e035c86f6af3dcb68cd |
publicationDate |
2020-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2020317805-A1 |
titleOfInvention |
Split superantigens and their use for immunotherapy |
abstract |
The invention refers to a split superantigen, divided into two fragments that by itself do not exhibit biologic activity, only upon dimerization they regain T cell activity. Scope of the invention is a screening method for detection of effective split superantigen designs, where split superantigen fragments are fused with coiled-coil forming peptides. The present invention relates to the field of cancer immunology. Each split superantigen fragment is fused with antibody or other tumor antigen specific protein, therefore only upon the binding of split superantigen-antibody fusion proteins to the tumor antigen, split superatigen fragments comes to proximity and reconstitute into biologically active form that activates T-cell response. |
priorityDate |
2017-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |